

# Jeremy P Grummet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9280032/publications.pdf>

Version: 2024-02-01

71  
papers

4,459  
citations

218677

26  
h-index

114465

63  
g-index

72  
all docs

72  
docs citations

72  
times ranked

4370  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Utility of <sup>68</sup> Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology. <i>European Urology Oncology</i> , 2022, 5, 314-320.	5.4	15
2	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 674-689.	3.1	21
3	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2022, 8, 690-700.	3.1	10
4	“Pain-free TRUS Bâ™: a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501). <i>BJU International</i> , 2022, 129, 591-600.	2.5	5
5	<sup>68</sup> Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 341-349.	0.4	12
6	Re: NCCN Prostate Cancer Guidelines Version 1.2022 “ September 10, 2021. <i>European Urology</i> , 2022, 81, 218.	1.9	2
7	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. <i>European Urology</i> , 2022, 81, 337-346.	1.9	33
8	Augmented deep learning model for improved quantitative accuracy of MR-based PET attenuation correction in PSMA PET-MRI prostate imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 9-20.	6.4	29
9	Role of multiparametric prostate MRI in the management of prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 651-659.	2.2	24
10	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer”2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	1.9	1,545
11	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II”2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	1.9	633
12	European Association of Urology Position Paper on the Prevention of Infectious Complications Following Prostate Biopsy. <i>European Urology</i> , 2021, 79, 11-15.	1.9	41
13	Predictors of erectile dysfunction after transperineal template prostate biopsy. <i>Investigative and Clinical Urology</i> , 2021, 62, 159.	2.0	3
14	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2021, 80, 531-545.	1.9	21
15	Loss of <i>SNAI2</i> in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1048-1059.	3.0	9
16	<sup>68</sup> Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. <i>World Journal of Urology</i> , 2021, 39, 4117-4125.	2.2	1
17	A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. <i>European Urology Oncology</i> , 2021, 4, 405-423.	5.4	26
18	Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 519-528.	5.4	10

#	ARTICLE	IF	CITATIONS
19	CX-5461 Sensitizes DNA Damage Repairâ€“proficient Castrate-resistant Prostate Cancer to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2140-2150.	4.1	9
20	Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution. <i>Translational Andrology and Urology</i> , 2021, 10, 3591-3603.	1.4	7
21	TREXIT Is Now: Should We Abandon the Transrectal Route for Prostate Biopsy? Yes. <i>European Urology Open Science</i> , 2021, 31, 14-16.	0.4	5
22	Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. <i>International Journal of Cancer</i> , 2020, 146, 161-168.	5.1	54
23	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. <i>European Urology Focus</i> , 2020, 6, 231-234.	3.1	131
24	Detection and localisation of primary prostate cancer using <sup>68</sup> gallium prostateâ€“specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. <i>BJU International</i> , 2020, 126, 83-90.	2.5	69
25	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>European Urology</i> , 2020, 77, 614-627.	1.9	101
26	Prostate-specific Membrane Antigen Positron Emission Tomography Scans Before Curative Treatment: Ready for Prime Time?. <i>European Urology</i> , 2020, 78, e125-e128.	1.9	3
27	â€œTREXIT 2020â€ why the time to abandon transrectal prostate biopsy starts now. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 62-65.	3.9	68
28	Transperineal prostate biopsy: a review of technique. <i>Translational Andrology and Urology</i> , 2020, 9, 3009-3017.	1.4	29
29	Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e21875.	4.3	57
30	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813.	1.9	151
31	Establishing a cryopreservation protocol for patientâ€“derived xenografts of prostate cancer. <i>Prostate</i> , 2019, 79, 1326-1337.	2.3	12
32	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. <i>European Urology</i> , 2019, 75, 699-702.	1.9	8
33	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2019, 75, 967-987.	1.9	278
34	Editorial Comment. <i>Journal of Urology</i> , 2019, 201, 276-276.	0.4	0
35	Editorial Comment. <i>Journal of Urology</i> , 2019, 201, 1126-1126.	0.4	0
36	Lower risk of pelvic metalware infection with operative repair of concurrent bladder rupture. <i>ANZ Journal of Surgery</i> , 2018, 88, 560-564.	0.7	9

#	ARTICLE	IF	CITATIONS
37	Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer. <i>BJU International</i> , 2018, 122, 40-49.	2.5	108
38	Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. <i>European Urology</i> , 2018, 73, 316-321.	1.9	31
39	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. <i>European Urology</i> , 2018, 74, 562-572.	1.9	80
40	Acute scrotum –“ Torsion of the third testicle!. <i>Urology Case Reports</i> , 2018, 20, 92-93.	0.3	3
41	Prostate Cancer Management in an Ageing Population. <i>European Urology</i> , 2017, 72, 532-533.	1.9	5
42	Re: Marco Borghesi, Hashim Ahmed, Robert Nam, et al. Complications After Systematic, Random, and Image-guided Prostate Biopsy. <i>Eur Urol</i> 2017;71:353-65. <i>European Urology</i> , 2017, 71, e143-e144.	1.9	7
43	Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. <i>Urology</i> , 2017, 104, 11-21.	1.0	92
44	Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephalosporin prophylaxis. <i>World Journal of Urology</i> , 2017, 35, 1199-1203.	2.2	59
45	How to Biopsy. <i>Urologic Clinics of North America</i> , 2017, 44, 525-534.	1.8	21
46	Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients. <i>Research and Reports in Urology</i> , 2017, Volume 9, 27-35.	1.0	6
47	Transperineal vs. transrectal biopsy in MRI targeting. <i>Translational Andrology and Urology</i> , 2017, 6, 368-375.	1.4	36
48	Penthrox alone versus Penthrox plus periprostatic infiltration of local analgesia for analgesia in transrectal ultrasound-guided prostate biopsy. <i>ANZ Journal of Surgery</i> , 2016, 86, 139-142.	0.7	16
49	Response to Re: Transrectal ultrasound-guided biopsy sepsis and the rise in carbapenem antibiotic use. <i>ANZ Journal of Surgery</i> , 2016, 86, 316-317.	0.7	2
50	Planning for the post-antibiotic era –“ why we must avoid TRUS-guided biopsy sampling. <i>Nature Reviews Urology</i> , 2016, 13, 559-560.	3.8	12
51	Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasound-guided biopsy: the Victorian Transperineal Biopsy Collaboration experience. <i>BJU International</i> , 2015, 116, 568-576.	2.5	42
52	The state of <sc>TRUS</sc> biopsy sepsis: readmissions to Victorian hospitals with <sc>TRUS</sc> biopsy-related infection over 5 years. <i>BJU International</i> , 2015, 116, 49-53.	2.5	40
53	Patients with medical risk factors for chronic kidney disease are at increased risk of renal impairment despite the use of nephron-sparing surgery. <i>BJU International</i> , 2015, 116, 590-595.	2.5	29
54	Risk factors for infection following prostate biopsy - a case control study. <i>BMC Infectious Diseases</i> , 2015, 15, 580.	2.9	20

#	ARTICLE	IF	CITATIONS
55	Can magnetic resonance imaging solve the prostate cancer conundrum?. Medical Journal of Australia, 2015, 202, 410-411.	1.7	0
56	Primary apocrine adenocarcinoma of scrotum suspected as urothelial carcinoma metastasis: A clinical and pathological dilemma. Urology Annals, 2015, 7, 97.	0.6	3
57	Transrectal ultrasoundâ€guided biopsy sepsis and the rise in carbapenem antibiotic use. ANZ Journal of Surgery, 2015, 85, 931-935.	0.7	14
58	Transperineal prostate biopsy: templateâ€guided or freehand?. BJU International, 2015, 115, 681-683.	2.5	12
59	The predictive value of ARv7 expression in localized prostate cancer treated with abiraterone, degarelix, and bicalutamide.. Journal of Clinical Oncology, 2015, 33, 71-71.	1.6	5
60	Current practice of prostate biopsy in Australia and New Zealand: A survey. Urology Annals, 2015, 7, 315-9.	0.6	29
61	Significant impact of transperineal template biopsy of the prostate at a single tertiary institution. Urology Annals, 2015, 7, 428.	0.6	14
62	Is zero sepsis alone enough to justify transperineal prostate biopsy?. BJU International, 2014, 114, 3-4.	2.5	5
63	Sepsis and â€superbugsâ€™: should we favour the transperineal over the transrectal approach for prostate biopsy?. BJU International, 2014, 114, 384-388.	2.5	187
64	A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials, 2013, 34, 4777-4785.	11.4	53
65	The â€green whistleâ€™: A novel method of analgesia for transrectal prostate biopsy. BJU International, 2012, 110, 85-88.	2.5	11
66	Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. Canadian Urological Association Journal, 2011, 5, e156-e161.	0.6	7
67	Paraneoplastic syndromes in prostate cancer. Nature Reviews Urology, 2010, 7, 681-692.	3.8	46
68	Vesicourethral anastomosis with 2-octyl cyanoacrylate adhesive in an in vivo canine model. Urology, 2002, 60, 935-938.	1.0	15
69	Laser Welded Vesicourethral Anastomosis in an In Vivo Canine Model: A Pilot Study. Journal of Urology, 2002, 168, 281-284.	0.4	14
70	Laser welded vesicourethral anastomosis in an in vivo canine model: a pilot study. Journal of Urology, 2002, 168, 281-4.	0.4	3
71	A 12-year experience in the management of traumatic bladder rupture at an Australian level 1 trauma centre. Journal of Clinical Urology, 0, , 205141582210864.	0.1	0